Bank of Nova Scotia decreased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 6.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 752,756 shares of the biopharmaceutical company’s stock after selling 50,416 shares during the quarter. Bank of Nova Scotia’s holdings in Bristol Myers Squibb were worth $45,655,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the stock. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb in the fourth quarter worth about $25,000. Physician Wealth Advisors Inc. raised its holdings in shares of Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 202 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Bayban purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $32,000. 76.41% of the stock is currently owned by institutional investors.
Bristol Myers Squibb Stock Up 0.9% BMY stock opened at $62.05 on Friday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The firm’s fifty day simple moving average is $57.49 and its 200-day simple moving average is $58.03. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The company has a market capitalization of $126.70 billion, a P/E ratio of 17.43, a price-to-earnings-growth ratio of 0.18 and a beta of 0.23.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same period last year, the firm earned $1.80 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.34 earnings per share for the current year.
Bristol Myers Squibb Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.
Key Headlines Impacting Bristol Myers Squibb Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: Bristol Myers Squibb announced progress on a new lung cancer combination therapy, advancing the program into Phase 2. That suggests continued pipeline momentum and gives investors another potential long-term growth catalyst. Article Title Positive Sentiment: The company also expanded its pipeline with a first-in-human trial for BMS-986533, reinforcing the view that Bristol Myers is still investing in new drug candidates beyond its current blockbuster portfolio. Article Title Neutral Sentiment: Multiple previews ahead of Bristol Myers Squibb’s upcoming earnings report point to Wall Street expecting earnings growth and a possible beat, which may be supporting shares ahead of the release. Article Title Neutral Sentiment: An analyst note on Bristol Myers Squibb was published, but the headline indicates general commentary rather than a major new thesis change, so the market impact appears limited. Article Title Negative Sentiment: Broader healthcare commentary flagged some names to avoid, but Bristol Myers Squibb was not singled out; still, it reflects a mixed sentiment backdrop for the sector rather than a company-specific setback. Article Title Wall Street Analyst Weigh In A number of research analysts have recently issued reports on the company. Guggenheim reiterated a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Bank of America dropped their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research report on Friday, July 10th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $54.00 target price on shares of Bristol Myers Squibb in a research note on Monday, July 6th. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $61.25.
Read Our Latest Analysis on BMY
About Bristol Myers Squibb (Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Further Reading Five stocks we like better than Bristol Myers Squibb AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Plugging In: How Kinder Morgan Powers Up Profits Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECitigroup Issues Positive Forecast for United Rentals (NYSE:URI) Stock Price
NEXT HEADLINE »Fifth Third Bancorp Raises Holdings in Liberty Media Corporation – Liberty Formula One Series C $FWONK
When dividend yields start to creep up, it's worth taking a closer look for any potential warning signs. Bristol Myers Squibb (BMY +0.94%) is a leading pharmaceutical company and has been a high-yield dividend stock for some time. Shares have averaged a dividend yield of 3.4% over the past decade.
However, that yield has been abnormally high for most of the past two years. The stock yields 4.1% today, and it's been as high as 6% over the past 24 months. Is the dividend simply too good to be true at this point?
My take is that the dividend is fine right now, but that you'll also need to watch out for potential hurdles as key drugs lose patent exclusivity over the next few years.
Image source: The Motley Fool.
The financials back up Bristol Myers Squibb's juicy dividend for now There's a famous expression that money talks. Examining the financials is the best way to check whether a company can actually afford its dividend. Bristol Myers Squibb pays a quarterly dividend totaling $2.52 per share for the year. Wall Street analysts estimate that it will earn $6.34 per share this year, enough to cover the dividend 2.5 times over.
If you're not satisfied, you can double-check this by looking at free cash flow, since dividends are technically a cash expense. Bristol Myers Squibb has generated $5.83 per share in free cash flow over the past year, covering the dividend more than twice over. From a numbers standpoint, the company can genuinely afford its dividend, and quite easily. The near-term risk of a cut seems pretty low.
Today's Change
(
0.94
%) $
0.58
Current Price
$
62.09
Keep an eye on how the drugmaker navigates a looming patent cliff The coast isn't quite clear, though. Patents for some of Bristol Myers Squibb's top-selling drugs will expire over the next few years. As those patents expire, generics will flood the market at low prices, and sales for those branded drugs will crater. It's a normal part of a drug's lifecycle and happens all the time in the pharmaceutical business.
This situation is called a patent cliff, and Bristol Myers Squibb faces a pretty steep one. Eliquis and Opdivo could both face generic competition by 2028 -- and the two drugs combined for over $6.1 billion in sales last year, roughly half of the company's total revenue. Not all is lost, though: Even after the patents expire, branded sales won't go to zero overnight. Additionally, the company has a strong pipeline, and its growth portfolio of newer drugs is steadily taking the baton.
The market perceives Bristol Myers Squibb as a riskier stock these days, and that's not necessarily wrong. Fortunately, the dividend has lots of breathing room, and there's growth from newer drugs on the way. I could see management scaling back dividend growth, perhaps issuing smaller raises to conserve cash while the company navigates these sensitive years. But barring catastrophic failure, I think you can reasonably trust the stock's 4.1% yield now and in the future.
Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.
Life and the stock market are both about expectations, and rising above what is expected is often rewarded, while falling short can come with negative consequences. Investors might want to try to capture stronger returns by finding positive earnings surprises.
The ability to identify stocks that are likely to top quarterly earnings expectations can be profitable, but it's no simple task. Here at Zacks, our Earnings ESP filter helps make things easier.
The Zacks Earnings ESP, ExplainedThe Zacks Earnings ESP is more formally known as the Expected Surprise Prediction, and it aims to grab the inside track on the latest analyst estimate revisions ahead of a company's report. The idea is relatively intuitive as a newer projection might be based on more complete information.
With this in mind, the Expected Surprise Prediction compares the Most Accurate Estimate (being the most recent) against the overall Zacks Consensus Estimate. The percentage difference provides the ESP figure. The system also utilizes our core Zacks Rank to provide a stronger system for identifying stocks that might beat their next quarterly earnings estimate and possibly see the stock price climb.
Bringing together a positive earnings ESP alongside a Zacks Rank #3 (Hold) or better has helped stocks report a positive earnings surprise 70% of the time. Furthermore, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.
Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.
Should You Consider Bristol Myers Squibb?Now that we understand what the ESP is and how beneficial it can be, let's dive into a stock that currently fits the bill. Bristol Myers Squibb (BMY - Free Report) earns a #3 (Hold) right now and its Most Accurate Estimate sits at $1.60 a share, just six days from its upcoming earnings release on July 30, 2026.
By taking the percentage difference between the $1.60 Most Accurate Estimate and the $1.59 Zacks Consensus Estimate, Bristol Myers Squibb has an Earnings ESP of +0.51%. Investors should also know that BMY is one of a large group of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
BMY is part of a big group of Medical stocks that boast a positive ESP, and investors may want to take a look at UnitedHealth Group (UNH - Free Report) as well.
UnitedHealth Group is a Zacks Rank #1 (Strong Buy) stock, and is getting ready to report earnings on October 27, 2026. UNH's Most Accurate Estimate sits at $4.01 a share 95 days from its next earnings release.
UnitedHealth Group's Earnings ESP figure currently stands at +2.11% after taking the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $3.93.
BMY and UNH's positive ESP metrics may signal that a positive earnings surprise for both stocks is on the horizon.
Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>
Aureus Asset Management LLC cut its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 81.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,689 shares of the biopharmaceutical company’s stock after selling 15,997 shares during the period. Aureus Asset Management LLC’s holdings in Bristol Myers Squibb were worth $224,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Northwestern Mutual Investment Management Company LLC increased its holdings in shares of Bristol Myers Squibb by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after buying an additional 172 shares during the period. KCM Investment Advisors LLC boosted its holdings in Bristol Myers Squibb by 0.8% during the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock valued at $1,126,000 after acquiring an additional 174 shares during the period. Investment Research Partners LLC grew its position in Bristol Myers Squibb by 1.4% during the 4th quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock worth $708,000 after acquiring an additional 179 shares during the last quarter. ESG Planning DBA Harper Investing grew its position in Bristol Myers Squibb by 1.3% during the 4th quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock worth $745,000 after acquiring an additional 180 shares during the last quarter. Finally, REAP Financial Group LLC increased its stake in Bristol Myers Squibb by 26.1% in the 4th quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 182 shares during the period. 76.41% of the stock is owned by institutional investors.
Bristol Myers Squibb News Roundup Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: BMY was highlighted as rising while the broader market dipped, suggesting investors were rotating into the name and viewing it as relatively resilient versus the market. Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts Positive Sentiment: Wall Street expectations point to earnings growth in next week’s report, and multiple articles framed Bristol Myers Squibb as having a strong chance to beat estimates, which can support the stock into the print. Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts Positive Sentiment: An analyst-style momentum piece also described BMY as a top long-term momentum stock, reinforcing a constructive technical/relative-strength narrative. Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term Neutral Sentiment: Bristol Myers Squibb is scheduled to report quarterly earnings next week, keeping the stock in a wait-and-see mode as investors look for confirmation of growth and guidance. Bristol Myers Squibb (BMY) to Release Quarterly Earnings on Thursday Neutral Sentiment: News that Alexandria Real Estate delivered a new Bristol Myers Squibb R&D hub in San Diego is operationally positive, but it is more of a long-term business development update than an immediate stock catalyst. Alexandria Real Estate Equities Delivers 427,000 RSF Bristol Myers Squibb R & D Hub Negative Sentiment: One MarketWatch item noted BMY underperformed peers despite daily gains, which suggests the move may be less impressive on a relative basis than it first appears. Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains Bristol Myers Squibb Stock Performance Shares of BMY stock opened at $61.56 on Friday. The stock has a fifty day moving average of $57.39 and a 200 day moving average of $58.00. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The firm has a market capitalization of $125.71 billion, a price-to-earnings ratio of 17.29, a PEG ratio of 0.17 and a beta of 0.23. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same period in the previous year, the firm earned $1.80 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.34 earnings per share for the current year.
Bristol Myers Squibb Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s payout ratio is currently 70.79%.
Analyst Upgrades and Downgrades BMY has been the subject of several recent research reports. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Weiss Ratings downgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 16th. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Bank of America dropped their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Finally, Guggenheim reissued a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $61.25.
Read Our Latest Report on Bristol Myers Squibb
Bristol Myers Squibb Profile (Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Articles Five stocks we like better than Bristol Myers Squibb Premium Retail’s Stress Test Is Separating Winners From Losers D-Wave Quantum or a Quantum ETF: Which Is the Better Bet? GE Vernova Just Sent a Mixed AI Signal to Investors Alphabet Crushed Earnings, But One Number Spooked the Market Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAssetmark Inc. Sells 35,135 Shares of SS&C Technologies Holdings, Inc. $SSNC
NEXT HEADLINE »28,761 Shares in AngloGold Ashanti PLC $AU Bought by ABN Amro Investment Solutions
In the latest trading session, Bristol Myers Squibb (BMY - Free Report) closed at $61.40, marking a +1.05% move from the previous day. The stock outpaced the S&P 500's daily loss of 1.21%. Elsewhere, the Dow lost 0.97%, while the tech-heavy Nasdaq lost 2.15%.
The biopharmaceutical company's shares have seen an increase of 10.47% over the last month, surpassing the Medical sector's gain of 3.97% and the S&P 500's gain of 0.42%.
Investors will be eagerly watching for the performance of Bristol Myers Squibb in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 30, 2026. In that report, analysts expect Bristol Myers Squibb to post earnings of $1.59 per share. This would mark year-over-year growth of 8.9%. In the meantime, our current consensus estimate forecasts the revenue to be $11.67 billion, indicating a 4.87% decline compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $6.34 per share and a revenue of $47.48 billion, indicating changes of +3.09% and -1.48%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Bristol Myers Squibb. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.35% increase. Bristol Myers Squibb is currently sporting a Zacks Rank of #3 (Hold).
In the context of valuation, Bristol Myers Squibb is at present trading with a Forward P/E ratio of 9.58. For comparison, its industry has an average Forward P/E of 18.84, which means Bristol Myers Squibb is trading at a discount to the group.
One should further note that BMY currently holds a PEG ratio of 0.17. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.54 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 93, which puts it in the top 38% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
The market expects Bristol Myers Squibb (BMY - Free Report) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on July 30, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis biopharmaceutical company is expected to post quarterly earnings of $1.59 per share in its upcoming report, which represents a year-over-year change of +8.9%.
Revenues are expected to be $11.67 billion, down 4.9% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.12% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Bristol Myers?For Bristol Myers, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.51%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that Bristol Myers will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Bristol Myers would post earnings of $1.44 per share when it actually produced earnings of $1.58, delivering a surprise of +9.72%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Bristol Myers appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry PlayerAmong the stocks in the Zacks Medical - Biomedical and Genetics industry, uniQure (QURE - Free Report) , is soon expected to post loss of $0.89 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of -29%. This quarter's revenue is expected to be $7.05 million, up 34% from the year-ago quarter.
The consensus EPS estimate for uniQure has been revised 0.5% higher over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +12.03%.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that uniQure will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
ABN Amro Investment Solutions boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 14.0% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 112,131 shares of the biopharmaceutical company’s stock after acquiring an additional 13,812 shares during the quarter. ABN Amro Investment Solutions’ holdings in Bristol Myers Squibb were worth $6,801,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after acquiring an additional 2,743,759 shares during the last quarter. State Street Corp raised its holdings in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after purchasing an additional 1,385,206 shares during the last quarter. Geode Capital Management LLC lifted its position in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after purchasing an additional 6,084,046 shares during the period. Norges Bank acquired a new position in Bristol Myers Squibb during the fourth quarter valued at $1,947,272,000. Finally, AQR Capital Management LLC boosted its holdings in Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after purchasing an additional 16,332,924 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.
Bristol Myers Squibb Stock Down 0.2% NYSE BMY opened at $60.79 on Thursday. The business has a fifty day moving average price of $57.29 and a 200 day moving average price of $57.94. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The company has a market cap of $124.14 billion, a P/E ratio of 17.08, a P/E/G ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the business posted $1.80 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.
Bristol Myers Squibb Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.
Analyst Ratings Changes A number of research firms have weighed in on BMY. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Guggenheim restated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Cantor Fitzgerald reissued a “neutral” rating and issued a $54.00 price target on shares of Bristol Myers Squibb in a report on Monday, July 6th. Finally, Weiss Ratings lowered Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 16th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $61.25.
Get Our Latest Stock Analysis on Bristol Myers Squibb
Bristol Myers Squibb Profile (Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Further Reading Five stocks we like better than Bristol Myers Squibb Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAureus Asset Management LLC Takes Position in Dell Technologies Inc. $DELL
NEXT HEADLINE »Alamar Capital Management LLC Invests $2.10 Million in Tenet Healthcare Corporation $THC
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Bristol Myers Squibb (BMY - Free Report) New York-based Bristol Myers is one of the leading global specialty biopharmaceutical companies focused on developing treatments targeting severe diseases. Blockbuster immuno-oncology drug Opdivo maintains momentum on consistent label expansions. The company’s efforts to revive its portfolio amid generic competition for legacy drugs like Revlimid, Pomalyst, Sprycel and Abraxane are impressive.
BMY is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. BMY has a Momentum Style Score of B, and shares are up 9.7% over the past four weeks.
Eight analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.02 to $6.34 per share. BMY also boasts an average earnings surprise of +16.5%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, BMY should be on investors' short list.
Everybody across the stock and bond markets breathed a huge sigh of relief when the consumer and producer price index numbers for June were released. The reality is that those great prints were largely due to plummeting gasoline prices, as the U.S. and Iran had temporarily halted hostilities under a signed memorandum of understanding. Now, after a stretch that recently included 10 straight bombing attacks on Iran, and despite the Iranian foreign ministry saying that discussions could continue, it looks like President Trump is prepared to go for the knockout punch. Regardless of the outcome, the Bank of America team argues that inflation is still well above the Federal Reserve’s target and that the right move is to start raising rates soon.
In a recent research report, the Bank of America’s Global Research Bureau of Economic Analysis team said this:
In our latest US economic weekly, we argued that the Federal Reserve should resume raising rates rather than remain on hold. A key pillar of our view is that underlying inflation remains meaningfully above the Fed’s 2% target. To be sure, June core PCE at 3.3% y/y (our estimate) likely overstates underlying inflation because it reflects several temporary or idiosyncratic factors. If we, however, exclude these influences, core PCE would still be 2.5% and little changed from a year ago. In our view, the combination of persistently elevated core inflation and a stable, if not improving, labor market argues for tighter monetary policy rather than an extended pause.
Before the June break in the fighting and the tumbling energy prices, in May, the energy shock we may experience again had driven inflation higher, with the CPI rising 4.2%, the sharpest increase in three years and well above the Fed’s 2% target. That in turn prompted lenders to demand higher rates to protect returns. Meanwhile, investors are selling bonds once again amid rising inflation and concerns about U.S. debt, lifting Treasury yields. Since mortgage rates are based on the 10-year Treasury yield plus a risk premium, they rose in tandem. On the fiscal side, federal interest payments now exceed spending on Medicaid, national defense, and all nondefense discretionary programs combined, adding further upward pressure on long-term borrowing costs. Experts say rates will only fall if geopolitical tensions ease, oil prices stabilize, and inflation remains under control, outcomes that remain uncertain at best.
Typically, when interest rates go higher, these four sectors tend to win:
Financials Energy Healthcare Industrials We screened our 24/7 Wall St. dividend stocks database for quality companies that pay big, dependable dividends and generate reliable passive income. We found four companies, one in each sector, that are solid bets if the upward trend in interest rates remains. All are rated Buy by the top Wall Street firms we cover.
Financials Financials are the biggest winner. Banks earn a wider spread between what they pay depositors and what they charge borrowers. Insurers earn more on their investment portfolios. The sector almost mechanically benefits from rising rates, as net interest income rises.
Based in Minneapolis, super-regional financial giant U.S. Bancorp (NYSE:USB | USB Price Prediction) is an outstanding choice for growth and income investors now, offering a hefty 3.29% dividend. The financial services holding company’s segments are:
Wealth Corporate Commercial and Institutional Banking Consumer and Business Banking Payment Services Treasury and Corporate Support It offers a comprehensive range of financial services, including lending and deposit services, cash management, capital markets, and trust and investment management services. It also engages in credit card services, merchant and ATM processing, mortgage banking, insurance, brokerage, and leasing.
The company’s banking subsidiary, U.S. Bank National Association (USBNA), is engaged in the banking business, principally in domestic markets. USBNA provides a range of products and services to individuals, businesses, institutional organizations, governmental entities, and other financial institutions.
The non-banking subsidiaries offer investment and insurance products to customers primarily within their domestic markets, as well as fund administration services to a range of mutual and other funds.
Oppenheimer has an Outperform rating with a target price of $77.
Energy Energy benefits because rate hikes typically coincide with inflation, and oil/gas prices are a primary driver of inflation. Higher commodity prices mean higher revenues. It is the inflation hedge play, and it has been the strongest-performing S&P sector so far in 2026.
Enterprise Products Partners (NYSE:EPD) is an American midstream natural gas and crude oil pipeline company headquartered in Houston, Texas. This company is one of the most extensive publicly traded energy partnerships, paying a very reliable 5.87% dividend. Its debt-to-EBITDA ratio ranges from 3.1x to 3.4x, which is moderate for a midstream energy company, and its interest coverage ratio is 5x.
The company generates strong free cash flow, with an operating cash flow of approximately $8.8 billion, resulting in approximately $4.2 billion in free cash flow annually after deducting capital expenditures. Another significant benefit for shareholders is that most of the corporate debt is fixed-rate, thereby limiting the risk of rising interest rates.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Bristol Myers Squibb didn't make the cut. Grab the names FREE today.
Its various midstream energy services include:
Gathering Processing Transporting and storing natural gas, natural gas liquids (NGL), and fractionation Import and export terminalling Offshore production platform services The company has four reportable business segments:
Natural Gas Pipelines and Services NGL Pipelines and Services Petrochemical Services Crude Oil Pipelines and Services One reason many analysts like the stock might be its distribution coverage ratio. The company’s coverage ratio is well above 1x, making it relatively less risky among the MLPs.
UBS has a Buy rating with a $45 target price.
Healthcare Pricing power and steady demand insulate the top healthcare names. They don’t directly benefit from higher rates, but they tend to hold up well because their earnings do not erode as much as those of interest-sensitive sectors.
Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company. This remains a solid pharmaceutical stock to own for the long term, offering an outstanding entry point and a reliable 4.12% dividend. The company is committed to discovering, developing, and delivering transformative medicines for patients with serious diseases across oncology, hematology, immunology, cardiovascular disease, neuroscience, and other therapeutic areas.
Its platforms comprise chemically synthesized or small-molecule drugs, including protein degraders, as well as biologics produced through biological processes. These platforms also encompass ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics.
Small-molecule drugs are typically administered orally in tablet or capsule form, although other drug-delivery mechanisms are also used. Biologics are usually administered by injection or intravenous infusion. CAR-T cell therapies are administered by intravenous infusion.
Eliquis Revlimid Pomalyst/Imnovid Sprycel Abraxane Bank of America has a Buy rating with a $66 price objective.
Industrials Industrial stocks often perform well in rising-rate environments because rate hikes can signal a strengthening and expanding economy. As businesses ramp up activity, demand for heavy equipment, machinery, and manufacturing capacity increases. This allows these cyclical companies to secure stronger order books and exercise greater pricing power, more than enough to offset their higher cost of capital.
Stanley Black & Decker (NYSE:SWK) is the world’s largest tool company, with 50 manufacturing facilities in the United States and more than 100 worldwide, and shares trade at 13.5 times forward earnings estimates. With the potential for the economy to slow down somewhat, you can bet that the do-it-yourself legions will fix rather than buy new, and this legendary stock is a solid idea now, while yielding a large 3.8% dividend.
The company provides hand tools, power tools, outdoor products, and related accessories in the United States, Canada, Other Americas, Europe, and Asia. Its Tools & Outdoor segment offers professional-grade corded and cordless electric power tools and equipment, including:
Drills Impact wrenches and drivers Grinders, saws, routers, and sanders Pneumatic tools and fasteners, such as nail guns, nails, staplers and staples, and concrete and masonry anchors; corded and cordless electric power tools Hand-held vacuums, paint tools, and cleaning appliances Leveling and layout tools, planes, hammers, demolition tools, clamps, vises, knives, saws, chisels, and industrial and automotive tools Drill bits, screwdriver bits, router bits, abrasives, saw blades, and threading products Toolboxes, sawhorses, metal cabinets, and engineered storage solutions Electric and gas-powered lawn and garden products This segment sells its products under brand names including:
Dewalt Craftsman Black+Decker Stanley Flex Volt Irwin Lenox The Industrial segment provides:
Threaded fasteners, blind rivets and tools, blind inserts and tools Drawn arc weld studs and systems Engineered plastic and mechanical fasteners Self-piercing riveting systems Precision nut running systems Micro fasteners High-strength structural fasteners Axle swage, latches, heat shields, pins, couplings, fittings, and other engineered products Attachments used on excavators and handheld tools The segment sells its products through a direct sales force and third-party distributors to various industries, including automotive, manufacturing, electronics, construction, aerospace, and others.
Barclays has an Overweight rating and a $95 price target.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Bristol Myers Squibb didn't make the cut. Grab the names FREE today.
Bessemer Group Inc. boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 19.6% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 70,632 shares of the biopharmaceutical company’s stock after purchasing an additional 11,584 shares during the quarter. Bessemer Group Inc.’s holdings in Bristol Myers Squibb were worth $4,283,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Swiss RE Ltd. acquired a new position in shares of Bristol Myers Squibb during the 4th quarter valued at $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the second quarter worth $25,000. Physician Wealth Advisors Inc. grew its holdings in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the period. Bayban bought a new stake in Bristol Myers Squibb in the fourth quarter valued at $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb in the fourth quarter valued at $32,000. 76.41% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets BMY has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Bank of America decreased their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Guggenheim reissued a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Finally, Weiss Ratings downgraded Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $61.25.
Get Our Latest Stock Analysis on BMY
More Bristol Myers Squibb News Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA partnership and plans to deploy a DGX SuperPOD based on Vera Rubin systems, which the company says will become the most powerful AI factory in life sciences and should enhance drug discovery and development efficiency. Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer Positive Sentiment: The company also said it will be the first life sciences firm to buy Nvidia’s latest DGX SuperPOD system, signaling an aggressive investment in AI infrastructure that could strengthen Bristol Myers’ competitive position in future drug research. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: A Reuters report repeated the AI-infrastructure news, reinforcing the strategic nature of the announcement but adding no materially new information for investors. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: Bristol Myers was mentioned in a broader article about cancer-drug competition and next-generation therapies, but the piece mainly discussed the market landscape rather than any company-specific development. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. Negative Sentiment: Healthcare stocks fell late Monday afternoon, which may be creating a modest drag on BMY and offsetting some of the optimism from the NVIDIA partnership news. Sector Update: Healthcare Stocks Fall Late Afternoon Bristol Myers Squibb Stock Down 0.7% Shares of NYSE BMY opened at $60.30 on Tuesday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The company has a 50-day moving average price of $57.11 and a 200-day moving average price of $57.85. The stock has a market capitalization of $123.14 billion, a P/E ratio of 16.94, a P/E/G ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.
Bristol Myers Squibb Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.
About Bristol Myers Squibb (Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Further Reading Five stocks we like better than Bristol Myers Squibb The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBessemer Group Inc. Boosts Stock Holdings in Enphase Energy, Inc. $ENPH
NEXT HEADLINE »Fifth Third Bancorp Acquires Shares of 75,857 Franklin FTSE Japan ETF $FLJP
Andra AP fonden cut its stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 51.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 332,662 shares of the biopharmaceutical company’s stock after selling 348,938 shares during the period. Andra AP fonden’s holdings in Bristol Myers Squibb were worth $20,176,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of BMY. waypoint wealth counsel bought a new position in Bristol Myers Squibb in the fourth quarter valued at about $1,194,000. Life Cycle Investment Partners Ltd acquired a new position in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $34,406,000. Axxcess Wealth Management LLC raised its holdings in Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after buying an additional 21,196 shares during the last quarter. Daytona Street Capital LLC acquired a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $1,362,000. Finally, Pensionfund Sabic acquired a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $1,845,000. Institutional investors and hedge funds own 76.41% of the company’s stock.
Bristol Myers Squibb Stock Down 0.7% Shares of Bristol Myers Squibb stock opened at $60.30 on Tuesday. The stock’s 50-day moving average is $57.11 and its 200 day moving average is $57.85. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The firm has a market cap of $123.14 billion, a price-to-earnings ratio of 16.94, a PEG ratio of 0.17 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company’s revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.34 EPS for the current year.
Bristol Myers Squibb Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 70.79%.
Analyst Ratings Changes Several equities analysts have issued reports on the stock. Weiss Ratings cut shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Bank of America cut their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a report on Friday, July 10th. Cantor Fitzgerald restated a “neutral” rating and issued a $54.00 price objective on shares of Bristol Myers Squibb in a report on Monday, July 6th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Finally, Guggenheim reaffirmed a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $61.25.
View Our Latest Report on BMY
More Bristol Myers Squibb News Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA partnership and plans to deploy a DGX SuperPOD based on Vera Rubin systems, which the company says will become the most powerful AI factory in life sciences and should enhance drug discovery and development efficiency. Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer Positive Sentiment: The company also said it will be the first life sciences firm to buy Nvidia’s latest DGX SuperPOD system, signaling an aggressive investment in AI infrastructure that could strengthen Bristol Myers’ competitive position in future drug research. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: A Reuters report repeated the AI-infrastructure news, reinforcing the strategic nature of the announcement but adding no materially new information for investors. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: Bristol Myers was mentioned in a broader article about cancer-drug competition and next-generation therapies, but the piece mainly discussed the market landscape rather than any company-specific development. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. Negative Sentiment: Healthcare stocks fell late Monday afternoon, which may be creating a modest drag on BMY and offsetting some of the optimism from the NVIDIA partnership news. Sector Update: Healthcare Stocks Fall Late Afternoon Bristol Myers Squibb Company Profile (Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
See Also Five stocks we like better than Bristol Myers Squibb The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECorning Incorporated $GLW Shares Purchased by Andra AP fonden
NEXT HEADLINE »Andra AP fonden Decreases Stock Holdings in Garmin Ltd. $GRMN
Assetmark Inc. cut its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 14.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 144,837 shares of the biopharmaceutical company’s stock after selling 24,825 shares during the period. Assetmark Inc.’s holdings in Bristol Myers Squibb were worth $8,784,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $25,000. Physician Wealth Advisors Inc. lifted its stake in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares during the period. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Bayban acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $32,000. 76.41% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In A number of research analysts recently issued reports on the stock. Weiss Ratings downgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Bank of America reduced their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $54.00 price target on shares of Bristol Myers Squibb in a research note on Monday, July 6th. Guggenheim reiterated a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Finally, UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus target price of $61.25.
Read Our Latest Stock Report on BMY
Bristol Myers Squibb Stock Performance NYSE BMY opened at $60.30 on Tuesday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The firm has a market cap of $123.14 billion, a price-to-earnings ratio of 16.94, a PEG ratio of 0.17 and a beta of 0.23. The company has a fifty day moving average price of $57.11 and a 200-day moving average price of $57.85.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period last year, the firm earned $1.80 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts predict that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.
Bristol Myers Squibb Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.
More Bristol Myers Squibb News Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA partnership and plans to deploy a DGX SuperPOD based on Vera Rubin systems, which the company says will become the most powerful AI factory in life sciences and should enhance drug discovery and development efficiency. Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer Positive Sentiment: The company also said it will be the first life sciences firm to buy Nvidia’s latest DGX SuperPOD system, signaling an aggressive investment in AI infrastructure that could strengthen Bristol Myers’ competitive position in future drug research. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: A Reuters report repeated the AI-infrastructure news, reinforcing the strategic nature of the announcement but adding no materially new information for investors. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: Bristol Myers was mentioned in a broader article about cancer-drug competition and next-generation therapies, but the piece mainly discussed the market landscape rather than any company-specific development. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. Negative Sentiment: Healthcare stocks fell late Monday afternoon, which may be creating a modest drag on BMY and offsetting some of the optimism from the NVIDIA partnership news. Sector Update: Healthcare Stocks Fall Late Afternoon Bristol Myers Squibb Company Profile (Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
See Also Five stocks we like better than Bristol Myers Squibb The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBioNTech SE Sponsored ADR $BNTX Shares Sold by Baader Bank Aktiengesellschaft
NEXT HEADLINE »Baader Bank Aktiengesellschaft Purchases 64,353 Shares of TotalEnergies SE Sponsored ADR $TTE
AlTi Global Inc. reduced its position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 92.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 9,221 shares of the biopharmaceutical company’s stock after selling 105,548 shares during the period. AlTi Global Inc.’s holdings in Bristol Myers Squibb were worth $559,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after buying an additional 2,743,759 shares during the last quarter. State Street Corp increased its stake in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock valued at $5,285,065,000 after acquiring an additional 1,385,206 shares during the last quarter. Geode Capital Management LLC raised its stake in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares during the period. Norges Bank acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $1,947,272,000. Finally, AQR Capital Management LLC raised its position in shares of Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after buying an additional 16,332,924 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Wall Street Analysts Forecast Growth BMY has been the subject of a number of research reports. Weiss Ratings downgraded Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $54.00 price objective on shares of Bristol Myers Squibb in a research note on Monday, July 6th. Bank of America decreased their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Finally, Guggenheim restated a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average price target of $61.25.
Get Our Latest Stock Analysis on Bristol Myers Squibb
Bristol Myers Squibb Trading Down 0.7% NYSE:BMY opened at $60.30 on Tuesday. The business’s 50-day moving average is $57.11 and its two-hundred day moving average is $57.85. The firm has a market capitalization of $123.14 billion, a PE ratio of 16.94, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.
Bristol Myers Squibb Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 70.79%.
Key Stories Impacting Bristol Myers Squibb Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA partnership and plans to deploy a DGX SuperPOD based on Vera Rubin systems, which the company says will become the most powerful AI factory in life sciences and should enhance drug discovery and development efficiency. Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer Positive Sentiment: The company also said it will be the first life sciences firm to buy Nvidia’s latest DGX SuperPOD system, signaling an aggressive investment in AI infrastructure that could strengthen Bristol Myers’ competitive position in future drug research. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: A Reuters report repeated the AI-infrastructure news, reinforcing the strategic nature of the announcement but adding no materially new information for investors. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: Bristol Myers was mentioned in a broader article about cancer-drug competition and next-generation therapies, but the piece mainly discussed the market landscape rather than any company-specific development. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. Negative Sentiment: Healthcare stocks fell late Monday afternoon, which may be creating a modest drag on BMY and offsetting some of the optimism from the NVIDIA partnership news. Sector Update: Healthcare Stocks Fall Late Afternoon About Bristol Myers Squibb (Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Articles Five stocks we like better than Bristol Myers Squibb The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEASML Holding N.V. $ASML Shares Sold by AlTi Global Inc.
NEXT HEADLINE »Amova Asset Management Americas Inc. Sells 54,907 Shares of Nu Holdings Ltd. $NU
Dimensional Fund Advisors LP boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 2.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,762,589 shares of the biopharmaceutical company’s stock after acquiring an additional 520,330 shares during the period. Dimensional Fund Advisors LP owned approximately 0.92% of Bristol Myers Squibb worth $1,137,847,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in BMY. Norges Bank acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $1,947,272,000. AQR Capital Management LLC lifted its position in Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after purchasing an additional 16,332,924 shares during the period. Bank of New York Mellon Corp boosted its stake in Bristol Myers Squibb by 47.0% during the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after buying an additional 7,837,485 shares in the last quarter. Geode Capital Management LLC increased its holdings in Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after buying an additional 6,084,046 shares during the period. Finally, Man Group plc raised its stake in shares of Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after buying an additional 5,503,391 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.
Bristol Myers Squibb Trading Down 0.0% Shares of Bristol Myers Squibb stock opened at $60.71 on Monday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The stock has a market capitalization of $123.97 billion, a P/E ratio of 17.05, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. The company has a 50-day simple moving average of $57.02 and a 200 day simple moving average of $57.80. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the business earned $1.80 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.
Bristol Myers Squibb Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s payout ratio is currently 70.79%.
Analyst Ratings Changes A number of research firms have recently commented on BMY. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Bank of America dropped their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price objective on shares of Bristol Myers Squibb in a report on Monday, July 6th. Guggenheim reiterated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Finally, UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $61.25.
View Our Latest Stock Analysis on BMY
Key Headlines Impacting Bristol Myers Squibb Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in relapsed/refractory multiple myeloma, a meaningful regulatory step that could strengthen the company’s oncology pipeline and future revenue prospects. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma Positive Sentiment: Unusual options activity showed traders buying a notably higher-than-average number of call options, suggesting some investors are positioning for additional upside in BMY. Positive Sentiment: Recent commentary highlighted Bristol Myers Squibb as a strong value stock, reinforcing the view that the shares may still look attractive on valuation grounds. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock Neutral Sentiment: Brokerage coverage continues to point to a “Hold” consensus, indicating analysts are not broadly turning more bullish or bearish on the stock. Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Hold” from Brokerages Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate to $6.10 from $6.12, but the change is modest and still near consensus, so it is unlikely to be a major near-term driver by itself. Negative Sentiment: The small downward revision to longer-term earnings expectations may indicate some caution around Bristol Myers Squibb’s post-2026 growth trajectory, which could limit enthusiasm if investors focus on future profitability. Bristol Myers Squibb Company Profile (Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Further Reading Five stocks we like better than Bristol Myers Squibb Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEDimensional Fund Advisors LP Acquires 270,950 Shares of Tesla, Inc. $TSLA
NEXT HEADLINE »Dimensional Fund Advisors LP Sells 14,438 Shares of Equinix, Inc. $EQIX
Item 1 of 2 Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration
[1/2]Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
CompaniesNEW YORK, July 20 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Monday it is buying the latest-generation computing system from chip company Nvidia (NVDA.O), opens new tab to support its use of artificial intelligence across its drug discovery and development operations.
The drugmaker said it will be the first life sciences company to buy an Nvidia DGX SuperPOD based on its Vera Rubin systems. The chipmaker unveiled its Vera Rubin architecture earlier this year as the successor to its current generation of AI computing systems.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Financial terms of the Bristol Myers investment were not disclosed. It builds on a smaller SuperPOD system the drugmaker bought from Nvidia, which is around two or three generations behind Vera Rubin, BMS executives said in an interview.
Pharmaceutical companies are increasingly investing in AI infrastructure to try to identify drug targets faster and improve the odds that experimental drugs succeed in clinical trials.
Robert Plenge, chief research officer at Bristol Myers, said the new capabilities would allow the company to cycle through many more potential drug candidates early in the drug development cycle.
"Maybe before we could do 10 and now we can do dozens," he said.
Plenge also said that the company is already using AI tools to cut the time to make medicines to test in trials by 20% to 30%. That could even reach 50% in coming years, he said.
He said one experimental sickle cell disease treatment currently in early clinical development by the company would likely not have been discovered if not for AI-enabled research.
Greg Meyers, the company's chief digital and technology officer, said the investment was driven in part by rapidly growing computing demands as Bristol deploys larger AI models across its research organization. It uses AI in all of its small-molecule and most of its large-molecule programs.
He also said the new system will be more energy efficient.
"When you host these things, you have to pay an electric bill," Meyers said. "Think of it as 10 times more compute capacity per watt spent ... Electricity is not getting cheaper."
Reporting by Michael Erman; editing by David Gaffen
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Allspring Global Investments Holdings LLC grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 5.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,095,654 shares of the biopharmaceutical company’s stock after acquiring an additional 57,224 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.05% of Bristol Myers Squibb worth $67,635,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth approximately $1,947,272,000. AQR Capital Management LLC lifted its holdings in Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after purchasing an additional 16,332,924 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after purchasing an additional 7,837,485 shares during the period. Geode Capital Management LLC grew its holdings in Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Finally, Man Group plc grew its holdings in Bristol Myers Squibb by 280.4% during the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after buying an additional 5,503,391 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.
Analyst Upgrades and Downgrades Several brokerages have weighed in on BMY. Guggenheim reissued a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Cantor Fitzgerald reissued a “neutral” rating and issued a $54.00 price objective on shares of Bristol Myers Squibb in a report on Monday, July 6th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Bristol Myers Squibb in a report on Thursday, July 2nd. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and a consensus price target of $61.25.
Get Our Latest Research Report on Bristol Myers Squibb
Bristol Myers Squibb Trading Up 0.3% Shares of BMY stock opened at $60.71 on Friday. The firm’s 50 day moving average price is $57.02 and its two-hundred day moving average price is $57.78. The stock has a market cap of $123.97 billion, a price-to-earnings ratio of 17.05, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the business earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.34 EPS for the current year.
Bristol Myers Squibb Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 70.79%.
Key Bristol Myers Squibb News Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in relapsed/refractory multiple myeloma, a meaningful regulatory step that could strengthen the company’s oncology pipeline and future revenue prospects. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma Positive Sentiment: Unusual options activity showed traders buying a notably higher-than-average number of call options, suggesting some investors are positioning for additional upside in BMY. Positive Sentiment: Recent commentary highlighted Bristol Myers Squibb as a strong value stock, reinforcing the view that the shares may still look attractive on valuation grounds. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock Neutral Sentiment: Brokerage coverage continues to point to a “Hold” consensus, indicating analysts are not broadly turning more bullish or bearish on the stock. Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Hold” from Brokerages Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate to $6.10 from $6.12, but the change is modest and still near consensus, so it is unlikely to be a major near-term driver by itself. Negative Sentiment: The small downward revision to longer-term earnings expectations may indicate some caution around Bristol Myers Squibb’s post-2026 growth trajectory, which could limit enthusiasm if investors focus on future profitability. Bristol Myers Squibb Company Profile (Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Articles Five stocks we like better than Bristol Myers Squibb AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident GE Aerospace Faces a Prove-It Moment in Q2 Earnings Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEiShares Russell 2000 ETF $IWM Shares Acquired by Allspring Global Investments Holdings LLC
NEXT HEADLINE »Allspring Global Investments Holdings LLC Purchases 285,364 Shares of Cintas Corporation $CTAS
Bristol Myers Squibb (BMY - Free Report) closed the most recent trading day at $60.48, moving +2.99% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.51%. At the same time, the Dow lost 0.2%, and the tech-heavy Nasdaq lost 1.47%.
Heading into today, shares of the biopharmaceutical company had gained 6.22% over the past month, outpacing the Medical sector's gain of 3.63% and the S&P 500's gain of 0.53%.
The upcoming earnings release of Bristol Myers Squibb will be of great interest to investors. The company's earnings report is expected on July 30, 2026. The company is forecasted to report an EPS of $1.59, showcasing a 8.9% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.67 billion, down 4.87% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.34 per share and revenue of $47.47 billion, which would represent changes of +3.09% and -1.5%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Bristol Myers Squibb. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.31% rise in the Zacks Consensus EPS estimate. Bristol Myers Squibb is currently a Zacks Rank #3 (Hold).
Looking at valuation, Bristol Myers Squibb is presently trading at a Forward P/E ratio of 9.26. This denotes a discount relative to the industry average Forward P/E of 18.95.
It is also worth noting that BMY currently has a PEG ratio of 0.17. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.52 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 100, positioning it in the top 41% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Bristol Myers Squibb (BMY - Free Report) New York-based Bristol Myers is one of the leading global specialty biopharmaceutical companies focused on developing treatments targeting severe diseases. Blockbuster immuno-oncology drug Opdivo maintains momentum on consistent label expansions. The company’s efforts to revive its portfolio amid generic competition for legacy drugs like Revlimid, Pomalyst, Sprycel and Abraxane are impressive.
BMY is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.26; value investors should take notice.
Seven analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.02 to $6.34 per share. BMY boasts an average earnings surprise of +16.5%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, BMY should be on investors' short list.
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Bristol Myers Squibb (BMY - Free Report) , which belongs to the Zacks Medical - Biomedical and Genetics industry.
This biopharmaceutical company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 9.64%.
For the last reported quarter, Bristol Myers came out with earnings of $1.58 per share versus the Zacks Consensus Estimate of $1.44 per share, representing a surprise of 9.72%. For the previous quarter, the company was expected to post earnings of $1.15 per share and it actually produced earnings of $1.26 per share, delivering a surprise of 9.57%.
Price and EPS Surprise
With this earnings history in mind, recent estimates have been moving higher for Bristol Myers. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Bristol Myers has an Earnings ESP of +0.86% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on July 30, 2026.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Bristol Myers Squibb (BMY - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this biopharmaceutical company have returned +1.8%, compared to the Zacks S&P 500 composite's +1.6% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Bristol Myers falls in, has gained 2.4%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Bristol Myers is expected to post earnings of $1.59 per share, indicating a change of +8.9% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.9% over the last 30 days.
The consensus earnings estimate of $6.33 for the current fiscal year indicates a year-over-year change of +2.9%. This estimate has changed +0.1% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $6.08 indicates a change of -3.9% from what Bristol Myers is expected to report a year ago. Over the past month, the estimate has changed +0.5%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Bristol Myers.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Bristol Myers, the consensus sales estimate of $11.65 billion for the current quarter points to a year-over-year change of -5.1%. The $47.47 billion and $46.05 billion estimates for the current and next fiscal years indicate changes of -1.5% and -3%, respectively.
Last Reported Results and Surprise HistoryBristol Myers reported revenues of $11.49 billion in the last reported quarter, representing a year-over-year change of +2.6%. EPS of $1.58 for the same period compares with $1.8 a year ago.
Compared to the Zacks Consensus Estimate of $10.92 billion, the reported revenues represent a surprise of +5.25%. The EPS surprise was +9.72%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Bristol Myers is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Bristol Myers. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Key Takeaways Bristol Myers Squibb's mezigdomide NDA for RRMM received FDA acceptance with a May 13, 2027, action date.BMY is advancing multiple CELMoD candidates and protein degrader programs across hematology and oncology.Bristol Myers Squibb's iberdomide NDA for RRMM has Priority Review with an Aug. 17, 2026, action date. Bristol Myers Squibb (BMY - Free Report) recently announced that the FDA has accepted its new drug application (NDA) for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM).
The regulatory body has granted a target action date of May 13, 2027 for this indication.
Mezigdomide is an oral cereblon E3 ligase modulator, or CELMoD, for the treatment of multiple myeloma.
It was developed using BMY’s targeted protein degradation platform (TPD), built over two decades.
BMY boasts a deep and promising pipeline. Key pipeline candidates with multi-billion-dollar potential are milvexian (Oral factor XIa inhibitor), admilparant (LPA1 antagonist), pumitamig (PD-L1 x VEGF-A bispecific antibody) and iberdomide & mezigdomide (oral CELMoD protein degraders).
BMY is the only drugmaker to have successfully developed and commercialized protein degrader therapies for multiple myeloma through its immunomodulatory drugs (IMiDs), which have become a standard of care for the disease.
The company is advancing a broad pipeline of investigational protein degraders using three complementary approaches — CELMoD agents, ligand-directed degraders (LDDs) and degrader antibody conjugates (DACs). By leveraging multiple degradation technologies, the company aims to target disease-causing proteins that were previously difficult to treat, expanding opportunities across hematology, oncology and other therapeutic areas.
Mezigdomide is also being evaluated in the ongoing phase III SUCCESSOR-1 study versus standard of care regimen in relapsed or refractory multiple myeloma.
BMY’s pipeline also includes iberdomide, an investigational, oral CELMoD, in combination with daratumumab, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma, and golcadomide, a potential first-in-class investigational CELMoD for lymphoma CELMoD.
The FDA has accepted a new drug application for iberdomide in combination with standard treatment (daratumumab and dexamethasone) for RRMM, granting Breakthrough Therapy Designation and Priority Review, with a target action date of Aug. 17, 2026.
BMY’s Competition in Oncology SpaceOncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space.
The company competes with big pharma giants like Merck (MRK - Free Report) and Pfizer (PFE - Free Report) in this space.
The immuno-oncology space is dominated by pharma giant MRK’s blockbuster drug Keytruda (pembrolizumab).
Keytruda is approved for several types of cancer and alone accounts for around 55% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.
Pfizer is one of the largest and most successful drugmakers in the field of oncology. It has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immune-oncology biologics that treat a wide range of cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, including lung cancer.
Pfizer’s position in oncology was strengthened with the addition of Seagen.
The company inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China.
BMY’s Price Performance, Valuation & EstimatesShares of Bristol Myers have gained 10% year to date compared with the industry’s growth of 3.3%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, shares currently trade at 9.58X forward earnings, higher than its mean of 8.61X but lower than the large-cap pharma industry’s 18.59X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 EPS has moved north to $6.32 from $6.30 in the past 60 days, while that for 2027 has moved north to $6.09 from $6.05 in the same time frame.
Drug pricing has been hanging over the pharmaceutical industry for years, and the Trump administration didn't eliminate that pressure. It did, however, pursue voluntary pricing agreements with many of the industry's largest drugmakers. Since late 2025, the Trump administration has reached voluntary most-favored-nation (MFN) pricing agreements with 17 of the world's largest pharmaceutical manufacturers, including Pfizer (PFE +1.32%), AbbVie (ABBV 0.03%), and Bristol Myers Squibb (BMY +3.06%).
These agreements generally align prices for certain drugs with those paid in comparable developed countries, expand discounted direct-to-consumer purchasing through the TrumpRx platform, and provide MFN pricing for certain Medicaid purchases. So the obvious question is: Will lower drug prices automatically translate into lower profits? Let's take a closer look and find out.
Image source: Getty Images.
Pfizer moved first Pfizer became the first major pharmaceutical company to reach an agreement with the administration, offering discounts on more than 30 branded medicines. Management has framed the initiative as a way to improve affordability while preserving incentives for pharmaceutical innovation.
Now, that might appear negative for revenue; lower prices generally mean the company makes less per prescription. But Pfizer has another problem that arguably matters more: It needs to replace revenue lost from the decline of its COVID-19 products. The company's own projections assumes an additional $1.5 billion decline in COVID-related revenue, separate from revenue pressure caused by patent expirations.
Today's Change
(
1.32
%) $
0.32
Current Price
$
24.49
That said, Pfizer is investing heavily in oncology, vaccines, and obesity treatments, while pursuing additional cost reductions. A clearer pricing framework, even if it results in somewhat lower prices, could reduce regulatory uncertainty and help management make longer-term capital allocation decisions.
AbbVie has more flexibility Compared to Pfizer, AbbVie enters this environment from a position of strength. You see, Humira, once the world's best-selling drug, has already faced years of biosimilar competition. Management spent considerable time preparing for that transition with newer immunology drugs Skyrizi and Rinvoq, which now drive much of the company's growth.
Those products continue posting strong double-digit percentage sales increases, giving AbbVie a much more diversified business than it had just a few years ago. Skyrizi has become one of its most important growth drivers, generating nearly $4.5 billion in first-quarter 2026 sales, up 31% from a year earlier. Rinvoq continues delivering strong growth across multiple autoimmune diseases, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, and atopic dermatitis. In the first quarter, Rinvoq revenue increased 23% year over year to roughly $2.1 billion, making it one of AbbVie's fastest-growing blockbuster medicines.
Today's Change
(
-0.03
%) $
-0.08
Current Price
$
248.00
Together, the two therapies are generating billions of dollars in annual revenue and are expected to more than offset the decline in Humira sales over the next several years. That transition leaves AbbVie less dependent on a single blockbuster drug and better positioned to absorb future pricing pressure.
Bristol Myers Squibb needs to fill a gap Bristol Myers Squibb faces a different challenge, as drug pricing isn't its only issue. Several of its top-selling products are already approaching (or facing) patent expirations, meaning they will be hit with competition from cheaper imitations. Revlimid has been steadily losing revenue as generic competition expands, while Eliquis, its blockbuster blood thinner co-marketed with Pfizer, is expected to face similar pressure later this decade.
Together, those products have generated tens of billions of dollars in annual sales, leaving Bristol Myers with a significant revenue gap to fill. Management has responded by launching newer medicines, expanding its late-stage pipeline, and pursuing acquisitions to strengthen its oncology, immunology, and cardiovascular portfolios. Whether those newer therapies can replace the revenue lost from aging blockbusters will likely have a much greater impact on long-term earnings than modest changes in drug pricing.
Today's Change
(
3.06
%) $
1.76
Current Price
$
59.34
The industry appears to be adapting So far, it seems as though the industry is adapting calmly, without any major red flags. And rather than mounting broad public opposition, many large pharmaceutical companies have chosen to negotiate. By April 2026, agreements included manufacturers that represent roughly 86% of the branded U.S. pharmaceutical market.
This is mostly the result of investor behavior. It's no secret that investors generally dislike regulatory uncertainty more than they dislike modest reductions in profitability. And the agreements may also provide other benefits, including tariff relief for participating manufacturers that expand U.S. production under separate administration policies. To put it simply: Complying, rather than fighting, was the most reasonable and sound strategy.
To be sure, drug pricing is becoming a larger factor in pharmaceutical investing, but it shouldn't become the only factor. Pipeline quality, research productivity, acquisitions, and manufacturing execution will continue driving long-term shareholder returns.
For Pfizer, the priority remains rebuilding growth beyond COVID products. For AbbVie, it's sustaining momentum from Skyrizi and Rinvoq. For Bristol Myers, success depends largely on replacing aging blockbuster products with next-generation therapies.
The new pricing agreements certainly change the industry's operating environment. But they don't eliminate what has always mattered most in pharmaceuticals: Companies that consistently develop valuable new medicines tend to create the most value for shareholders over time.
The agency assigned a Prescription Drug User Fee Act target action date of May 13, 2027, with the filing supported by positive Phase 3 SUCCESSOR-2 trial results.
• Bristol-Myers Squibb stock is building positive momentum. Why are BMY shares climbing?
FDA Accepts Mezigdomide ApplicationMezigdomide is an oral cereblon E3 ligase modulator (CELMoD), being developed to treat multiple myeloma.
The NDA seeks approval of the combination regimen, known as MeziKd, for patients with relapsed or refractory disease.
He noted Bristol Myers Squibb now has two separate agents under FDA review for relapsed or refractory multiple myeloma, adding that the company continues to advance its CELMoD pipeline across blood cancers and solid tumors.
Phase 3 SUCCESSOR-2 Trial ResultsThe NDA is based on data from the Phase 3 SUCCESSOR-2 study, which evaluated MeziKd against the standard regimen of carfilzomib and dexamethasone (Kd).
According to the company, the combination delivered a clinically meaningful and statistically significant improvement in progression-free survival.
Median progression-free survival reached 18.0 months compared with 8.3 months for the control arm, translating to a 52% reduction in the risk of disease progression or death (HR: 0.48).
The benefit was observed in patients with relapsed or refractory multiple myeloma, including those receiving treatment after a prior anti-CD38 monoclonal antibody and lenalidomide.
Safety Profile and Next StepsBristol Myers Squibb said the safety profile of MeziKd was consistent with findings from previous mezigdomide studies and aligned with the known safety profiles of the individual medicines included in the regimen.
The company also acknowledged the patients and investigators who participated in the Phase 3 SUCCESSOR-2 trial.
BMY Stock Price Activity: Bristol-Myers Squibb shares were up 2.29% at $58.90 at the time of publication on Monday, according to Benzinga Pro data.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma.
Bristol Myers Squibb (BMY +3.98%) belongs to an elite group. Only two other large-cap healthcare stocks offer higher dividend yields. Bristol Myers Squibb's juicy yield of 4.3% is absolutely grabbing the attention of many income investors.
The drugmaker has paid a dividend for an impressive 94 consecutive years. Bristol Myers Squibb has increased its dividend for 17 straight years. But is its dividend safe now? Here's what investors need to know.
Image source: Getty Images.
The coverage, the cliff, and the catalysts Let's start with some good news. Bristol Myers Squibb's dividend payout ratio currently stands at 70%. While a lower ratio is preferable, the pharma giant's earnings are more than sufficient to cover its dividend right now.
Sure, Bristol Myers Squibb didn't generate enough free cash flow in the first quarter of 2026 to fund its dividend program. However, this reflected the negative impact of lower Eliquis pricing that should be largely offset later this year by lower rebate payments.
The bad news for Bristol Myers Squibb's dividend, though, is the company's looming patent cliff. Blockbuster drugs Eliquis and Opdivo lose patent exclusivity in 2028. These two products generated roughly half of Bristol Myers Squibb's total revenue last year.
However, the patent cliff is only part of the story. Bristol Myers Squibb's growth portfolio now represents the majority of the company's total revenue. Sales for newer products, including cancer immunotherapies Breyanzi and Opdualag, autoimmune disease drug Sotyktu, and schizophrenia therapy Cobenfy, are growing rapidly. The drugmaker's pipeline also features around 50 programs in development, several of which hold the potential to be growth catalysts.
Today's Change
(
3.98
%) $
2.22
Current Price
$
58.03
The verdict My take is that Bristol Myers Squibb's 4.3% dividend yield is safe, at least for the next couple of years. What about beyond that point? I'm cautiously optimistic.
I expect that Bristol Myers Squibb's growth portfolio will generate enough revenue that the company will be able to avoid cutting its dividend later this decade. It wouldn't surprise me, though, if the streak of dividend increases comes to a screeching halt.
That said, it's still possible that the patent cliff could hurt Bristol Myers Squibb worse than I'm anticipating. The drugmaker's debt also totaled $44.5 billion at the end of the first quarter of 2026. That's manageable but coud become problematic if the growth portfolio and pipeline don't deliver as I think they will.
I wouldn't completely rule out a dividend cut in the future. However, I still view this pharma stock as a good pick for income investors over the near term (and potentially over the long term, too).
SummaryBristol Myers Squibb remains a Strong Buy, supported by steady performance and undervaluation despite recent underperformance versus the benchmark.BMY boasts a 4.43% forward dividend yield, over 2.7x the sector median, with 36 years of uninterrupted payments and 18 years of consecutive growth.Recent double-beat earnings and consistent estimate beats since 2024 reinforce positive sentiment and justify a premium valuation.Legacy drug headwinds persist, but current pricing likely reflects these risks; analysts' $63 price target implies 11% upside.2.02K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BMY over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Bristol Myers Squibb (BMY - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this biopharmaceutical company have returned +5.8%, compared to the Zacks S&P 500 composite's -1.8% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Bristol Myers falls in, has gained 6.2%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Bristol Myers is expected to post earnings of $1.62 per share for the current quarter, representing a year-over-year change of +11%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.2%.
The consensus earnings estimate of $6.32 for the current fiscal year indicates a year-over-year change of +2.8%. This estimate has remained unchanged over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $6.09 indicates a change of -3.6% from what Bristol Myers is expected to report a year ago. Over the past month, the estimate has changed +0.5%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Bristol Myers is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Bristol Myers, the consensus sales estimate of $11.67 billion for the current quarter points to a year-over-year change of -4.9%. The $47.38 billion and $46.07 billion estimates for the current and next fiscal years indicate changes of -1.7% and -2.8%, respectively.
Last Reported Results and Surprise HistoryBristol Myers reported revenues of $11.49 billion in the last reported quarter, representing a year-over-year change of +2.6%. EPS of $1.58 for the same period compares with $1.8 a year ago.
Compared to the Zacks Consensus Estimate of $10.92 billion, the reported revenues represent a surprise of +5.25%. The EPS surprise was +9.72%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Bristol Myers is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Bristol Myers. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Bristol Myers Squibb (BMY - Free Report) New York-based Bristol Myers is one of the leading global specialty biopharmaceutical companies focused on developing treatments targeting severe diseases. Blockbuster immuno-oncology drug Opdivo maintains momentum on consistent label expansions. The company’s efforts to revive its portfolio amid generic competition for legacy drugs like Revlimid, Pomalyst, Sprycel and Abraxane are impressive.
BMY is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.26; value investors should take notice.
Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.02 to $6.32 per share. BMY also boasts an average earnings surprise of +16.5%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, BMY should be on investors' short list.
In the latest close session, Bristol Myers Squibb (BMY - Free Report) was up +1.81% at $58.56. The stock outpaced the S&P 500's daily gain of 1.18%. Elsewhere, the Dow saw an upswing of 0.59%, while the tech-heavy Nasdaq appreciated by 2.07%.
The biopharmaceutical company's stock has climbed by 0.59% in the past month, falling short of the Medical sector's gain of 7.96% and outpacing the S&P 500's loss of 2.9%.
Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on July 30, 2026. The company's earnings per share (EPS) are projected to be $1.61, reflecting a 10.27% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.67 billion, down 4.89% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.32 per share and revenue of $47.39 billion, which would represent changes of +2.76% and -1.66%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.06% higher. Bristol Myers Squibb is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Bristol Myers Squibb's current valuation metrics, including its Forward P/E ratio of 9.1. This denotes a discount relative to the industry average Forward P/E of 21.95.
We can also see that BMY currently has a PEG ratio of 0.16. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.64.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 154, this industry ranks in the bottom 37% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Bristol Myers Squibb (BMY - Free Report) New York-based Bristol Myers is one of the leading global specialty biopharmaceutical companies focused on developing treatments targeting severe diseases. Blockbuster immuno-oncology drug Opdivo maintains momentum on consistent label expansions. The company’s efforts to revive its portfolio amid generic competition for legacy drugs like Revlimid, Pomalyst, Sprycel and Abraxane are impressive.
BMY is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. BMY has a Momentum Style Score of B, and shares are up 0.6% over the past four weeks.
For fiscal 2026, 10 analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.04 to $6.32 per share. BMY boasts an average earnings surprise of +16.5%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, BMY should be on investors' short list.
At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on.
Bristol Myers Squibb: Patent Cliff Meets a 41% Payout Ratio Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) just raised its payout for a 17th consecutive year, backed by 94 straight years of dividend payments.
Metric Value Annual dividend $2.52 Yield 4.63% Earnings payout ratio ~41% Net debt ~$33.6B Most recent raise 1.6% The Growth Portfolio rose 12% to $6.23B in Q1 2026, with Eliquis up 16% and Camzyos up 97%. CEO Christopher Boerner said BMY is “off to a good start in 2026, with first quarter results reflecting sustained momentum.” The Legacy book is shrinking 12% to 16% on generics, but a 41% payout leaves real cushion.
Verdict: Safe. Bull case: Growth Portfolio offsets the patent cliff. Bear case: Eliquis exclusivity erodes faster than expected and debt service crowds out raises.
Pfizer: The 6.6% Yield Is Earned the Hard Way Pfizer (NYSE:PFE) is the highest yielder here, and the coverage is the tightest.
Metric Value Annual dividend $1.72 Yield 6.64% 2025 FCF vs. dividends $9.08B / $9.77B FCF coverage 0.93x Net debt / EBITDA 3.26x Free cash flow covered just 93% of 2025 dividends, the first shortfall since 2023. Operating cash flow has slid from $32.6B in 2021 to $11.7B in 2025. CEO Albert Bourla called 2026 “an important year rich in key catalysts.” Buybacks are paused, with none anticipated in 2026, and the $7.0B Metsera obesity deal adds integration risk.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Verizon didn't make the cut. Grab the names FREE today.
Verdict: Moderate Risk. Bull case: pipeline and obesity bets refill the revenue gap. Bear case: LOE drag widens and FCF stays below the payout.
Verizon: 6% Yield, $172B in Debt, and Real Cash Flow Verizon (NYSE:VZ) raised its dividend for a 19th straight year after closing the Frontier acquisition.
Metric Value Annualized dividend ~$2.83 Yield 6.09% 2025 FCF $20.1B FCF payout ratio ~56% Net unsecured leverage 2.6x 2026 guidance calls for FCF of $21.5B+ against roughly $11.8B in dividends. CEO Dan Schulman said the “turnaround is not only progressing, it is gaining momentum” and raised adjusted EPS guidance to $4.95 to $4.99. Total debt of $172.5B is heavy, but 56% FCF coverage gives plenty of room.
Verdict: Safe. Bull case: fiber and postpaid phone adds (first positive Q1 since 2013) sustain cash flow. Bear case: refinancing Frontier debt at higher rates squeezes future raises.
For an income-focused retiree, BMY and VZ look like the dependable core of this trio; PFE is the higher-yield position that warrants the closest watch on quarterly cash flow.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Verizon didn't make the cut. Grab the names FREE today.
Choosing between established healthcare giants often comes down to balancing income needs against growth potential. Both Bristol Myers Squibb (BMY +3.07%) and Johnson & Johnson (JNJ +3.37%) offer massive scale but follow different strategic paths.
Bristol Myers Squibb focuses heavily on specialized biopharmaceuticals like oncology and cardiovascular care, while Johnson & Johnson operates a broader model spanning medicine and medical devices. Investors frequently compare them because they both provide essential medical solutions and consistent dividends, making them staples for those seeking stability.
Bristol Myers Squibb operates as a pure-play biopharmaceutical company focusing on serious diseases. The company develops and sells medicines in the healthcare stocks sector across oncology, hematology, and immunology. It distributes these products primarily through wholesalers and specialty pharmacies, utilizing specific risk-management programs for drugs like Revlimid.
In FY 2025, revenue reached approximately $48.2 billion. This represented a slight decline of nearly 0.2% compared to the prior year. However, the company reported net income of $7.1 billion, which resulted in a net margin of 14.6%. This was a significant recovery from the net loss reported in fiscal year 2024.
As of its December 2025 balance sheet, the debt-to-equity ratio was 2.6x. This means total debt is 2.6 times the value of shareholder equity. The current ratio, which measures the ability to cover short-term obligations with short-term assets, was 1.3x. Free cash flow, calculated as cash from operations minus capital expenditures, was nearly $12.8 billion.
The case for Johnson & JohnsonJohnson & Johnson is a global healthcare giant divided into Innovative Medicine and MedTech segments. The company serves patients across diverse areas including orthopaedics, surgery, and neuroscience. It is currently undergoing a strategic separation of its Orthopaedics business, a process expected to take up to 24 months to complete.
For FY 2025, revenue reached approximately $94.2 billion, indicating growth of roughly 6.0%. The company reported net income of nearly $26.8 billion. This performance resulted in a strong net margin of 28.5%, showcasing the company's ability to turn sales into profit.
According to its December 2025 balance sheet, the debt-to-equity ratio was approximately 0.6x. This indicates a conservative level of total debt relative to shareholder equity. The current ratio was 1.0x, showing that current assets roughly equaled current liabilities. Free cash flow for the period was close to $20 billion.
Risk profile comparisonBristol Myers Squibb faces significant pressure from the Inflation Reduction Act, which allows for government price negotiations on major drugs like Eliquis and Pomalyst. The company also deals with the loss of market exclusivity for key products like Revlimid, which can lead to rapid sales declines. Furthermore, manufacturing complex biologics and cell therapies creates risks related to supply chain disruptions and quality control.
Johnson & Johnson is also impacted by government price negotiations for products like Stelara and Xarelto. The company continues to manage significant legal risks, particularly regarding long-standing litigation over talc-based baby powder. It faces competition from other large firms like Merck and Pfizer.
Valuation comparisonBristol Myers Squibb currently trades at a significant discount to Johnson & Johnson when looking at future earnings estimates and sales multiples.
MetricBristol-Myers SquibbJohnson & JohnsonSector BenchmarkForward P/E8.8x20.8x24.8xP/S ratio2.4x6.2xSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Which stock would I buy in 2026?I'd go with Johnson & Johnson. Both companies are navigating patent cliffs on blockbuster drugs, which is one of the trickier challenges in big pharma. But the two companies are in noticeably different positions when it comes to what's on the other side of that challenge.
J&J is firing on multiple fronts. Its innovative medicine business is growing, its MedTech segment is expanding in cardiovascular and electrophysiology, and the company just raised its full-year outlook after a strong first quarter. With 28 products generating at least a billion dollars in annual revenue, this is a business with extraordinary staying power.
Bristol Myers Squibb is making progress too. Its newer growth brands are gaining traction and the pipeline has some interesting candidates. But overall revenue is expected to decline in 2026 as legacy products lose ground, and the path forward requires more patience.
For a long-term investor who wants steady growth and a solid dividend, J&J is the more comfortable bet.
An Intel Xeon 6 processor. Intel’s stock has surged recently. Technical indicators are still bullish. (Annabelle Chih/Bloomberg)
Looking back at past stock picks is important because it helps investors understand what worked, what didn’t, and why. It turns trading decisions into a learning process by separating skill from luck and highlighting patterns in both good and bad outcomes. Over time, this can improve discipline, sharpen strategy, and lead to more consistent decision-making.
Bristol Myers Squibb (BMY - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this biopharmaceutical company have returned -4.1%, compared to the Zacks S&P 500 composite's +1.6% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Bristol Myers falls in, has gained 0.9%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Bristol Myers is expected to post earnings of $1.61 per share for the current quarter, representing a year-over-year change of +10.3%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.6%.
For the current fiscal year, the consensus earnings estimate of $6.32 points to a change of +2.8% from the prior year. Over the last 30 days, this estimate has changed +0.1%.
For the next fiscal year, the consensus earnings estimate of $6.05 indicates a change of -4.3% from what Bristol Myers is expected to report a year ago. Over the past month, the estimate has changed -0.2%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Bristol Myers is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Bristol Myers, the consensus sales estimate of $11.67 billion for the current quarter points to a year-over-year change of -4.9%. The $47.39 billion and $46.06 billion estimates for the current and next fiscal years indicate changes of -1.7% and -2.8%, respectively.
Last Reported Results and Surprise HistoryBristol Myers reported revenues of $11.49 billion in the last reported quarter, representing a year-over-year change of +2.6%. EPS of $1.58 for the same period compares with $1.8 a year ago.
Compared to the Zacks Consensus Estimate of $10.92 billion, the reported revenues represent a surprise of +5.25%. The EPS surprise was +9.72%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Bristol Myers is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Bristol Myers. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Durable Responses And T-Cell Activity Highlight Potential BenefitTwo of the three patients maintained complete responses for at least eight months, with one ongoing complete response at >13 months.
In addition, all three patients demonstrated persistent mKRAS-specific T cell responses.
These results are particularly noteworthy as they suggest potential efficacy in a patient population that typically shows limited response to existing therapies.
Company Plans Combination Study In Metastatic KRAS Pancreatic CancerSubject to funding, Elicio plans to initiate a Phase 1 study evaluating ELI-002 7P in combination with standard gemcitabine/nab-paclitaxel chemotherapy and an anti-PD-1 inhibitor in treatment-naïve metastatic mKRAS pancreatic cancer.
The planned study is designed to prospectively evaluate the hypothesis generated by these observations and assess whether ELI-002 7P may enhance anti-tumor immunity and improve responsiveness to checkpoint inhibition.
Data May Guide Future Development StrategyThe news comes after the company released disappointing results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) following standard locoregional treatment.
While the trial did not achieve its pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population, the company pointed to early treatment benefits and subgroup findings that are shaping its planned Phase 3 program.
Elicio on Wednesday said it plans to use the study findings to evaluate checkpoint inhibitor combinations further and help inform future development strategies in metastatic PDAC and the adjuvant PDAC Phase 3 trial.
Analyst Consensus & Recent Actions:ELTX stock carries a Buy rating with an average price target of $21.75. Recent analyst moves include:
Jones Trading: Downgraded to Hold (June 16) HC Wainwright & Co.: Buy (Raises Target to $23.00) (June 15) B. Riley Securities: Initiated with Buy (Target $27.00) (June 10) ELTX Price Action: Elicio Therapeutics shares were up 28.80% at $3.55 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company.
The dividend is payable on August 3, 2026, to stockholders of record at the close of business on July 2, 2026.
About Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook, and Instagram.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2026 on Thursday, July 30, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:15 a.m. ET.
Investors and the general public are invited to listen to a live audio webcast of the call at http://investor.bms.com. Materials related to the call will be available on the company’s Investor Relations website prior to the start of the conference call.
A replay of the webcast will be available here approximately three hours after the conference call concludes.
About Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.
Bristol Myers Squibb (BMY +1.63%) shares have gone nowhere over the past few years. Why? The scariest two words in the pharmaceutical industry: "patent cliff." Just two medications -- Eliquis and Opdivo -- accounted for over $24.4 billion in sales last year, roughly half of total revenue. Market exclusivity for both drugs in the United States expires in 2028. At that point, the market will open, allowing lower-cost competitors to erode those sales.
The patent cliff creates a hole that the drugmaker must fill, and then some, if it wants to continue to grow. In that sense, it's hard to blame the market for growing skittish about the stock. But doubt and uncertainty can create opportunity. Here are three reasons to consider buying Bristol Myers Squibb shares like there's no tomorrow.
Image source: The Motley Fool.
1. It has a revamped drug portfolio and pipeline Fortunately, pharmaceutical companies can see patent cliffs from miles away. Bristol Myers Squibb has been preparing for this moment by investing in its pipeline, both organically and through acquisitions. The company has 50 compounds in development and aims to deliver 10 new medicines by the end of the decade.
Cobenfy is the most important. Already approved to treat schizophrenia, it has immense commercial potential if it wins approval for treating psychosis associated with Alzheimer's disease. A crucial readout from its phase 3 Adept-2 study is due out later this year. In a partnership with Johnson & Johnson, Bristol Myers Squibb is also developing Milvexian, a new anticoagulant for atrial fibrillation that could help offset lost sales from Eliquis; that drug is also undergoing phase 3 studies.
There are also approved drugs that are still ramping up. Sales of Camzyos grew 97% year over year in the first quarter to $314 million, Breyanzi grew 56% to $411 million, and Reblozyl grew 16% to $555 million. Overall, the drugs in Bristol Myers Squibb's growth portfolio grew sales by 12% in the first quarter, offsetting a 6% decline from legacy products, bringing companywide growth to 3% that quarter.
Bristol Myers Squibb will need to put more pipeline wins on the board, and it would be a big setback if Cobenfy's indication for Alzheimer's psychosis fails. But the pieces are in place for the company to fill the sales gap created by its coming patent cliff.
2. Its 4.6% dividend is well funded Of course, investors will have to wait and see how the pipeline matures over the next couple of years. The good news is that the stock will pay you to wait. Bristol Myers Squibb pays a dividend that yields a very generous 4.6% at the current share price. Despite the high yield, the company earns more than enough to pay shareholders: The dividend is currently only 40% of the company's 2026 earnings estimates.
That's an enormous margin of safety. If sales of Eliquis and Opdivo disappeared overnight, cutting Bristol Myers Squibb's earnings in half, the company could still afford its payouts. So you're getting paid a juicy, well-funded dividend while you wait for new products to fill that eventual sales gap.
Today's Change
(
1.63
%) $
0.89
Current Price
$
55.59
3. The stock is cheap Are there risks to investing in Bristol Myers Squibb? Yes. But the market has discounted the stock accordingly. I wouldn't be touting it if it traded at a price-to-earnings (P/E) ratio of 25, because there would be far more downside risk than potential reward if something went wrong. But the stock doesn't have a P/E of 25; it trades at only 8.5 times its 2026 earnings estimates.
I like to frame valuations as the market's way of setting expectations; a high valuation translates to high expectations. Bristol Myers Squibb's low valuation is the market's signal that it doesn't expect much growth. That may be fair if the company can't bring new drugs to market as it hopes to. But I think eking out mid-single-digit earnings growth through this patent cliff is enough to justify buying the stock now.
The stock's valuation could even remain at this low level indefinitely, and a smidge of growth could bring total annual returns into the high single digits because that 4.6% dividend provides such a high floor. If things go better than expected -- say Cobenfy hits a home run with Alzheimer's psychosis -- that low valuation would suddenly become a springboard to massive upside when Wall Street's sentiment improves.
In the latest close session, Bristol Myers Squibb (BMY - Free Report) was up +1.52% at $55.53. The stock's performance was ahead of the S&P 500's daily loss of 1.44%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq lost 2.22%.
The biopharmaceutical company's shares have seen a decrease of 8.01% over the last month, not keeping up with the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.
Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on July 30, 2026. In that report, analysts expect Bristol Myers Squibb to post earnings of $1.61 per share. This would mark year-over-year growth of 10.27%. Meanwhile, the latest consensus estimate predicts the revenue to be $11.67 billion, indicating a 4.89% decrease compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $6.32 per share and a revenue of $47.39 billion, demonstrating changes of +2.76% and -1.66%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.06% rise in the Zacks Consensus EPS estimate. Bristol Myers Squibb currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Bristol Myers Squibb has a Forward P/E ratio of 8.65 right now. This represents a discount compared to its industry average Forward P/E of 21.4.
Investors should also note that BMY has a PEG ratio of 0.16 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.47.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 156, finds itself in the bottom 37% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Key Takeaways FDA granted Priority Review to BMY's Camzyos filing for adolescents with symptomatic oHCM.Camzyos generated $314 million in Q1 sales, supported by growing demand and patient adoption.Bristol Myers seeks growth from Camzyos as patent expirations pressure legacy drug revenues. Bristol Myers Squibb (BMY - Free Report) is banking on label expansion of existing drugs and approval of new drugs to further propel its growth portfolio.
Camzyos (mavacamten) is one of the key drugs of this product portfolio. The drug is currently approved in the United States for adults with symptomatic New York Heart Association (“NYHA”) class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve symptoms and functional capacity.
The drug continued to gain traction in the targeted market in the first quarter, supported by growing demand and increased adoption among eligible patients. Sales of the drug totaled $314 million in the first quarter.
Earlier this month, the FDA accepted BMY’s supplemental new drug application (sNDA) seeking approval of Camzyos for the treatment of adolescents aged 12 to under 18 years with symptomatic oHCM.
The FDA granted Priority Review to the application with a target action date of Sept. 30, 2026.
If approved, Camzyos would become the first cardiac myosin inhibitor available for adolescents with oHCM and expand the drug's addressable market beyond adults.
For Bristol Myers, continued growth from Camzyos is particularly important as the company works to offset revenue pressures from patent expirations affecting the legacy drugs.
BMY’s cardiovascular portfolio also comprises blood thinner medicine Eliquis, for which BMY has a worldwide co-development and co-commercialization agreement with pharma giant Pfizer. Eliquis is one of the biggest contributors to the top line.
However, BMY’s cardiovascular portfolio suffered a hit in late 2025 after the company decided to discontinue the late-stage Librexia study on cardiovascular candidate milvexian, an investigational oral, highly selective factor XIa (FXIa) inhibitor.
BMY and partner Johnson & Johnson (JNJ - Free Report) were evaluating the efficacy and safety of pipeline candidate milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS) event.
Both companies decided to discontinue the phase III Librexia ACS study following a preplanned interim analysis by the Independent Data Monitoring Committee (“IDMC”), which determined that the study is unlikely to meet the primary efficacy endpoint.
The IDMC advised that the two other late-stage studies — Librexia AF for atrial fibrillation (AF) and Librexia STROKE for secondary stroke prevention (SSP) — should proceed as planned. Top-line data from these studies is expected in 2026.
Competition for BMY’s Cardiovascular DrugsIn December 2025, Cytokinetics (CYTK - Free Report) obtained FDA approval for aficamten for the treatment of patients with obstructive HCM in the United States, under the brand name Myqorzo.
This marks the company’s first FDA-approved product, transforming Cytokinetics from a development-stage biotech into a commercial-stage company.
The approval of Myqorzo is a significant boost for CYTK, given the market potential for the oHCM market.
JNJ’s Xarelto is also a Factor Xa inhibitor, similar to Eliquis.
However, JNJ is facing patent challenges for Xarelto in the United States. JNJ co-developed Xarelto with Bayer AG.
BMY’s Price Performance, Valuation & EstimatesShares of Bristol Myers have gained 4.3% year to date against the industry’s decline of 1.3%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, shares currently trade at 9.07X forward earnings, higher than its mean of 8.59X but lower than the large-cap pharma industry’s 17.79X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 EPS has moved north to $6.32 from $6.29 in the past 60 days, while that for 2027 has moved south to $6.05 from $6.08 in the same time frame.
With the 10-Year Treasury yielding 4.48% and the Fed signaling more cuts ahead, income investors are hunting for yield that compounds. Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) offers a 4.39% yield backed by 94 consecutive years of dividend payments. The pharma giant is rebuilding around a Growth Portfolio (Eliquis, Camzyos, Breyanzi) while legacy drugs face generic erosion. The question I want answered: is this payout actually safe?
Dividend Snapshot Metric Value Annual Dividend $2.52 per share Dividend Yield 4.39% Consecutive Increases 17 years Most Recent Increase 1.6% (February 2026) Aristocrat Status No (17 of 25 years) Payout Ratios Leave Real Room to Breathe BMY paid out roughly $5.15 billion in dividends against FY2025 non-GAAP EPS of $6.15, putting the earnings payout ratio near 41%. Through nine months of 2025, operating cash flow hit $6.3 billion, comfortably above the ~$3.9 billion of dividends paid in the same window.
Metric Value Assessment Earnings Payout Ratio ~41% Healthy OCF Coverage (9M 2025) ~1.6x Adequate 2026 EPS Guidance $6.05 to $6.35 Covers dividend 2.4x Leverage Is Elevated but Manageable Metric Value Assessment Net Debt ~$33.6B Elevated Net Debt / EBITDA ~1.8x Manageable EBITDA (TTM) $18.97B Strong Cash on Hand $9.57B Solid Buffer A dovish Fed matters here: lower refinancing costs on that ~$49B debt stack directly protect cash available for shareholders.
The Streak Is Intact, Growth Is Modest Year Annual Dividend 2026 $2.52 2025 $2.48 2024 $2.40 2023 $2.28 2022 $2.16 Recent hikes have decelerated to roughly 1.6%, signaling management is preserving capital for pipeline investment rather than chasing aggressive raises.
Management’s Tone Is Confident CEO Christopher Boerner told investors on the Q4 2025 call that BMY has “a strengthened balance sheet that provides the strategic flexibility to continue investing in growth drivers” and pointed to “industry-leading, sustainable growth into the 2030s and beyond”. That is the language of a team prioritizing the dividend.
Verdict: Safe, With Slower Growth Ahead Dividend Safety Rating: Safe. A ~41% earnings payout ratio, inelastic demand for oncology and immunology treatments, and 2026 EPS guidance that covers the payout more than twice over leave a real margin of safety. The dividend looks well-supported if the Growth Portfolio keeps expanding double-digits and pivotal readouts like the ADEPT trial and iberdomide’s August 17, 2026 PDUFA land favorably. The risk picture darkens if legacy erosion overshoots the guided 12-16% decline and debt paydown slows. The dividend is safe; future raises will likely stay modest.
Pharmaceutical giant Bristol Myers Squibb (BMY +0.26%) is offering investors a 4.5% yield. That is well above the 1% you'd collect from the S&P 500 index (SNPINDEX: ^GSPC ) and the 1.6% average for the drug sector. While the yield looks relatively attractive, given how high it is, prudent investors will wonder if the dividend is safe. It's highly likely that it is, and here's why.
Bristol Myers Squibb is a well-run business Bristol Myers Squibb isn't an upstart drug company; it has been in business for a very long time and is highly respected. Notably, its dividend hasn't been increased every year, but it has trended higher for decades. That's an indication of the company's strength as a business and of the board of directors' understanding of the dividend's value to shareholders.
Image source: Getty Images.
At the end of the day, it is the board of directors that will decide Bristol Myers Squibb's dividend policy. However, dividend investors should consider several key statistics when evaluating the safety of the drug maker's lofty yield. For example, the dividend payout ratio is around 72%. That's kind of high, but not outlandishly so. There's some room for adversity before a cut would likely be in the cards.
There are reasons to worry about Bristol Myers Squibb's dividend That said, Bristol Myers Squibb has some important drugs losing patent protection: Revlimid, Pomalyst, and Eliquis, which is marketed with Pfizer (PFE +0.15%). Patent loses will put material pressure on its top and bottom lines over the next couple of years. Although the company is working to develop new drugs to replace the lost revenue, timing mismatches between patent losses and new drug development are common in the pharmaceutical sector. The payout ratio could rise in the near term.
Today's Change
(
0.26
%) $
0.15
Current Price
$
57.05
Which is why a look at the company's balance sheet is equally important. For starters, Bristol Myers Squibb has an investment-grade credit rating, so it is financially strong. Notably, the debt-to-equity ratio is currently 2.2x, down from 3x at the end of 2024. Interest coverage is 6.3x, suggesting ample leeway for the company to meet its bond obligations. All of this suggests that, if needed, the company could take on additional debt to support its business and dividend if needed.
Not for super conservative investors, but not a huge risk either If you simply can't tolerate uncertainty, then maybe Bristol Myers Squibb's 4.5% yield won't be a good fit for your dividend portfolio. However, for most investors, the company's long and successful history, lofty but not unreasonable payout ratio, and strong financial position should provide ample confidence that the dividend will hold through the patent expiration headwinds Bristol Myers Squibb is facing right now.
Bristol Myers Squibb (BMY +0.40%) is a well-respected pharmaceutical company. Technically, it was created in 1989 through the merger of two other companies, but both of those businesses were founded in the 1800s. It is a proven survivor that clearly knows how to navigate the highly complex and competitive drug industry. And the stock looks cheap today. But is it really as cheap as it looks?
Bristol Myers Squibb's value appeal Bristol Myers Squibb's price-to-earnings ratio is currently sitting around 16x. That's well below the S&P 500's (^GSPC +0.50%) 27x and the pharmaceutical industry's 24x average. Meanwhile, Bristol Myers Squibb's dividend yield is a highly attractive 4.4%. By comparison, the S&P 500 index has a yield of 1.1%, and the average drug maker's yield is around 1.7%.
Image source: Getty Images.
It would be understandable if value investors jumped aboard. For dividend investors attracted to the lofty yield, the company's 70% payout ratio is a bit high but not unreasonably so. Still, you should ask yourself why the company looks attractively priced before you buy it.
The fly in Bristol Myers Squibb's ointment Bristol Myers Squibb isn't likely to go out of business anytime soon. If your investment horizon is decades long, you may want to own this stock today, given its attractive valuation metrics. However, you'll have to be prepared for some uncertainty through at least the end of 2028. That's because the company has key drugs with upcoming patent expirations. Revlimid and Pomalyst, both cancer drugs, will get hit in 2026, and cardiovascular drug Eliquis, which is marketed with competitor Pfizer (PFE +0.15%), is set to face generic competition in 2028.
Today's Change
(
0.40
%) $
0.23
Current Price
$
57.13
To be fair, the company has been working on its drug pipeline. But research and development don't work on a timeline, while patent expirations do. There could be a timing mismatch that leaves Bristol Myers Squibb's top and bottom lines under material pressure in the near term. So, the stock looks like it is a bargain, but there's a reason for the discounted price.
Bristol Myers Squibb is a long-term commitment The pharmaceutical business is intensely competitive. Bristol Myers Squibb has proven it knows how to survive in the long term, and the price has some value and income appeal today. However, it may not be as cheap as it seems when you factor in near-term patent headwinds. If you are hoping to make a quick buck, you should probably look elsewhere.
That said, if your plan is to hold the stock for decades, Bristol Myers Squibb may still be worth buying. After all, it is probably better to buy a good company at an attractive price than to try to time the bottom with every purchase, which is a virtually impossible task to do consistently.
Bristol Myers Squibb is mispriced as a melting ice cube, despite its Growth Portfolio surpassing Legacy revenues in Q1 2026. BMY's pipeline offers four near-term catalysts—including iberdomide, mezigdomide, milvexian, and Cobenfy—that could force a re-rating within seven months. Even using bearish consensus forecasts, BMY's DCF supports a $68.5/share valuation, about 20% above current levels, with downside well protected.
Interim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented at ASCO® 2026
SystImmune and Bristol Myers Squibb’s potent dual-targeted EGFRxHER3 bispecific antibody-drug conjugate has now demonstrated clinical benefit in three Phase 3 trials in China, underscoring its broad therapeutic potential in multiple tumor types
REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), reported positive results from prespecified interim analyses of two Phase 3 studies evaluating izalontamab brengitecan (iza-bren), an investigational and potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC). The studies demonstrated iza-bren achieved statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in heavily pretreated, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC; PANKU-Breast02/BL-B01D1-307) and recurrent or metastatic esophageal squamous cell carcinoma (ESCC; PANKU-Esophagus01/BL-B01D1-305). These data, presented at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting, support iza-bren’s potential as a new standard of care in these challenging cancer types.
$BMY and SystImmune announce new data for a dual-targeted EGFRxHER3 bispecific antibody-drug conjugate in triple negative breast cancer and metastatic esophageal squamous cell carcinoma at #ASCO26.
Share Iza-bren has now shown clinical benefit in three Phase 3 trials, underscoring its broad therapeutic potential. PANKU-Breast02 is the first Phase 3 study of a bispecific ADC to report positive results for dual primary endpoints of both PFS and OS in TNBC, while PANKU-Esophagus01 marks the first Phase 3 trial of a bispecific ADC in esophageal cancer to report positive dual primary endpoints of both PFS and OS. Iza-bren previously demonstrated positive phase 3 results in recurrent or metastatic nasopharyngeal carcinoma (NPC), presented at ESMO 2025.
“As a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate, iza-bren has now shown significant clinical benefit in three Phase 3 trials in different cancer types, and the strength of these data presented at ASCO further reinforce the value iza-bren can deliver over current standards of care,” said Dr. Yi Zhu, chief executive officer of Biokin. “We are proud to share these results as we continue to evaluate iza-bren to unlock the full potential of this dual mechanism of action to improve outcomes for patients in need.”
“Iza-bren can address a critical gap for patients who develop resistance or experience disease progression after prior therapies and may also hold potential in earlier lines of therapy,” said Cristian Massacesi, MD, executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “We have a broad development program for iza-bren and believe it has the potential to be a cornerstone treatment in a number of different cancers and easily combined with other therapies.”
Results from the Interim Analysis of PANKU-Breast02 (BL-B01D1-307)
The Phase 3 PANKU-Breast02 trial evaluated iza-bren in patients with unresectable locally advanced or metastatic TNBC whose disease progressed following 1-2 prior lines of systemic therapy for advanced disease, including prior taxane therapy. Patients were randomized 1:1 to receive iza-bren (n=207) or physician’s choice of chemotherapy (TPC; n=211), which included eribulin, capecitabine, gemcitabine, or vinorelbine. The study met both dual primary endpoints at a prespecified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in OS and BICR-assessed PFS with iza-bren compared to TPC.
With a median follow-up of 11 months, median OS was 15.9 months with iza-bren vs. 12.5 months with TPC (HR: 0.60; 95% CI: 0.42-0.85; p=0.0019) Median PFS by Blinded Independent Central Review (BICR) was 8.5 months with iza-bren vs. 3.1 months with TPC (HR: 0.29; 95% CI: 0.22-0.38; p<0.0001) The confirmed objective response rate (ORR) assessed by BICR was 51.7% with iza-bren compared to 20.5% with TPC (odds ratio, 4.3; 95% CI: 2.8-6.7) “While there have been significant advancements in breast cancer treatment, advanced triple-negative breast cancer has remained a challenge, with patients facing poor outcomes,” said Dr. Jiong Wu, Fudan University Shanghai Cancer Center. “These results highlight the potential for iza-bren to be a new standard of care as the first bispecific ADC to show improved progression-free and overall survival in a Phase 3 study in this patient population.”
Iza-bren showed a manageable safety profile in this heavily pre-treated patient population, with no new safety signals observed. Grade >3 treatment-emergent adverse events (TEAEs) were predominantly hematologic toxicities and consistent with the known safety profile of iza-bren. Any grade interstitial lung disease (ILD) was reported in 3 (1.4%; 1 case of grade 1 and 2 cases of grade 2) patients treated with iza-bren and 0 patients treated with TPC. Treatment discontinuation due to TEAEs occurred in 4 (1.9%) patients treated with iza-bren and 1 (0.5%) patients treated with TPC.
Results from the Interim Analysis of PANKU-Esophagus01 (BL-B01D1-305)
The Phase 3 PANKU-Esophagus01 trial evaluated iza-bren in patients with recurrent or metastatic esophageal squamous cell carcinoma who had progressed after first-line treatment with a PD-1/PD-L1 inhibitor plus platinum-based chemotherapy (n=249) compared to chemotherapy of physician’s choice (n=248). Results from the interim analysis show iza-bren demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of OS and BICR-assessed PFS.
Median OS was 9.8 months with iza-bren vs. 7.2 months with chemotherapy (HR: 0.64; 95% CI: 0.49-0.83; p=0.0004). Median PFS by BICR was 4.2 months with iza-bren vs. 2.0 months with chemotherapy (HR:0.50; 95% CI: 0.40-0.63; p<0.0001). Iza-bren also demonstrated an improvement in responses with an ORR by BICR of 35.3% compared to 13.1% with chemotherapy. “Metastatic esophageal squamous cell carcinoma is an aggressive disease with a five-year survival rate of less than 5%, and there remains a critical unmet need for treatment options after first-line immunotherapy and chemotherapy,” said Dr. Lin Shen, Peking University Cancer Hospital and Institute. “As the first Phase 3 clinical trial of a novel EGFRxHER3 bispecific antibody-drug conjugate to report positive data in this patient population, these results show the potential for iza-bren to set a new benchmark in significantly extending survival for patients with recurrent or metastatic esophageal squamous cell carcinoma.”
Iza-bren also showed a manageable safety profile in this patient population. Grade >3 treatment-related adverse events (TRAEs), which were predominantly hematologic toxicities, occurred in 85.1% of patients treated with iza-bren and 60.2% of patients who received chemotherapy. TRAEs that led to treatment discontinuation occurred in 2% of patients treated with iza-bren and 3.3% treated with chemotherapy. Treatment-related deaths occurred in 1.2% of patients treated with iza-bren and 1.6% of patients treated with chemotherapy. The rates of all grades and grade >3 ILD were low in the iza-bren arm (1.6%/0.8%) and the chemotherapy arm (0.4%/0.4%).
A New Drug Application for iza-bren for the treatment of recurrent or metastatic esophageal squamous cell carcinoma has been accepted by the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) and included in the priority review process.
The PANKU-Breast02 and PANKU-Esophagus01 studies are sponsored by SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), in Mainland China. Outside of China, iza-bren is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement.
About iza-bren
Iza-bren (BL-B01D1) is a bispecific antibody-drug conjugate (ADC) that targets both EGFR and HER3, which are highly expressed in various epithelial cancers and are known to be associated with cancer cell proliferation and survival. Iza-bren's dual mechanism of action blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. In addition, upon antibody mediated internalization, iza-bren's therapeutic novel Topo1i payload is released causing cytotoxic stress that leads to cancer cell death.
About SystImmune
SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has several assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development.
About Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.
SystImmune Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the potential clinical benefits of iza-bren, the timing and outcomes of regulatory interactions, and the future development and commercialization of iza-bren. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. SystImmune undertakes no obligation to update any forward-looking statements contained herein, except as required by law.
Bristol Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that future study results may not be consistent with the results to date, that izalontamab brengitecan (iza-bren) may not achieve its primary study endpoints or receive regulatory approvals for the indications described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether such treatment for such indication will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
Bristol Myers Squibb offers a compelling buy-the-dip opportunity with a forward P/E of 8.7x and a 4.6% dividend yield. BMY's diversified growth portfolio posted 9% YoY sales expansion, offsetting legacy drug declines and demonstrating early-stage growth runway. Upcoming pivotal clinical readouts in H2 2026, including milvexian and Cobenfy, are set to define BMY's long-term growth trajectory.
Over the past few years, Bristol Myers Squibb (BMY +0.40%) and Pfizer (PFE +0.15%), have underperformed broader equities. However, throughout it all, they have maintained their dividend programs intact and currently boast high yields. Bristol Myers' forward yield is a healthy 4.4%, while Pfizer's is even juicier at 6.6%. Neither company is out of the woods yet, though, as both still have challenges ahead, notably patent cliffs. Which one is the safer bet today for dividend seekers? Let's find out.
Image source: The Motley Fool.
The case for Bristol Myers Squibb Bristol Myers will lose patent exclusivity for Opdivo -- a cancer medicine -- and Eliquis, an anticoagulant it co-markets with Pfizer, by the end of the decade. These two are among the company's best-selling drugs. However, Bristol Myers could overcome these obstacles. The drugmaker's newer, subcutaneous formulation of Opdivo will help attract many older patients and offset losses from biosimilar competition, as it is much easier and faster to administer while still being about as effective.
Today's Change
(
0.40
%) $
0.23
Current Price
$
57.13
Bristol Myers is also working on a next-gen anticoagulant, milvexian. This medicine could address a key risk of traditional blood thinners, bleeding, and target many patients who are undertreated due to this potential side effect. Overall, Bristol Myers has a deep pipeline across oncology, immunology, and other therapeutic areas. The company also has a portfolio of newer drugs, some of which, like Reblozyl for anemia in patients with beta-thalassemia, are posting strong sales growth.
Lastly, Bristol Myers has increased its dividends by 65.8% over the past decade. The company still looks like a top pick for dividend seekers.
The case for Pfizer Besides Eliquis, Pfizer will lose patent exclusivity for other medicines by the end of the decade, including its cancer drug Ibrance. However, the company has newer products that are performing well. One of them is Abrysvo, a vaccine for the respiratory syncytial virus. Pfizer also has a deep pipeline that should yield tangible results over the next few years. The company plans to launch about 20 pivotal studies this year, after starting quite a few in 2025.
Today's Change
(
0.15
%) $
0.04
Current Price
$
26.21
Some of Pfizer's candidates look promising. The company's investigational weight loss medicine, MET-097i, is one of them. Another is Pfizer's next-gen cancer drug, PF'4404. Provided Pfizer can make solid progress with these programs (and others), the company's shares could recover. Lastly, Pfizer continues to increase its dividend, which is up 51.3% over the past 10 years. The stock may not have performed well over the last half-decade, but it could handsomely reward patient investors who stick with it for the long term.
Which is the better buy Between these two stocks, I would give Bristol Myers a slight edge right now, as its newer product portfolio looks better than Pfizer's. Bristol Myers also seems more prepared to overcome upcoming patent cliffs, especially that of Opdivo, thanks to the newer version of the drug. Further, Bristol Myers has grown its dividend faster over the past decade. Overall, it looks like a better income stock. However, those on the market for attractive, blue chip dividend stocks cannot go wrong with either company.
